Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
About Chromadex Corp
Chromadex Corp (CDXC) is a globally recognized integrated nutraceutical and bioscience company committed to improving the quality of life through advanced research on healthy aging. The company is deeply invested in understanding the mechanisms by which cellular processes, particularly those involving nicotinamide adenine dinucleotide (NAD+), impact the aging process. With a core focus on innovative science, Chromadex has developed a multifaceted business model that spans from research breakthroughs to commercially available consumer products, ensuring that its scientific discoveries translate into meaningful daily benefits.
Business Model and Core Segments
Chromadex’s operational framework is built on three primary segments that work in unison to deliver high-quality, science-based nutraceutical innovations:
- Consumer Products: This segment is primarily responsible for marketing and distributing products directly to the consumer market. Its portfolio features formulations designed to support healthy aging by leveraging proprietary, scientifically validated ingredients. The company’s flagship product, built around the NAD+ precursor nicotinamide riboside (NR), exemplifies its commitment to translating rigorous research into everyday solutions.
- Ingredients Segment: Focused on the development and licensing of novel ingredients, this segment utilizes high-caliber scientific research to create bioactive compounds. These innovations are targeted for use in various applications, ranging from dietary supplements to functional foods, ensuring that the expertise of Chromadex is shared widely across the industry.
- Analytical Reference Standards and Services: This area underpins the rigorous quality control and analytical validation processes that are crucial to research and product development. By offering specialized standards and services, Chromadex supports both internal development and external quality assurance needs in a scientifically robust manner.
Research and Innovation
At the heart of Chromadex’s operations is a steadfast commitment to research and development. The company partners with leading universities and research institutions worldwide to explore the potential of critical biochemical pathways related to aging. This collaborative approach not only strengthens its research capabilities but also ensures that the ingredients developed are based on solid scientific evidence. The integration of cutting-edge bioscience and precise analytical methodologies solidifies its position as a trusted name in the nutraceutical industry.
Market Position and Competitive Differentiation
Chromadex distinguishes itself by focusing on the intersection of scientific innovation and consumer wellness. Its emphasis on NAD+ research, an area that has increasingly become synonymous with the study of aging and cellular health, sets it apart in a competitive landscape that includes various bioscience and nutraceutical companies. The company’s multidimensional approach, which bridges direct consumer engagement with deep scientific inquiry, provides a unique value proposition that caters both to health-conscious individuals and to industry partners seeking high-quality, science-backed ingredients.
Commitment to Transparency and Quality
Transparency in research and product development is a core tenet of Chromadex’s philosophy. Every stage of its process—from initial scientific exploration to the final formulation—undergoes rigorous analytical review and quality control. This disciplined approach reassures consumers and industry collaborators alike, fostering trust and establishing Chromadex as a reliable source of scientifically supported nutraceutical innovations.
Integrating Science and Consumer Wellness
The company’s approach is marked by a detailed understanding of biochemical processes and a commitment to translating this expertise into practical health solutions. With its diversified business segments, Chromadex not only addresses the needs of a broad consumer base but also solidifies its reputation among researchers and industry experts. Its dedicated exploration of key ingredients such as nicotinamide riboside, alongside other innovative compounds, continues to influence the realm of healthy aging and functional nutrition.
ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, announces its participation in Canaccord Genuity's 44th Annual Growth Conference from August 13-15, 2024, in Boston. CEO Rob Fried and Interim CFO James Lee will present on August 14 and conduct one-on-one meetings throughout the event.
This prestigious conference, a 44-year cornerstone for industry leaders and investors, provides ChromaDex an opportunity to showcase its latest developments, strategic initiatives, and growth prospects. Interested parties can arrange meetings through the conference website or their CG representative.
ChromaDex's involvement underscores its commitment to engaging with investors and industry experts, potentially impacting its market position and future growth strategies in the healthy aging sector.
ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, has announced its Q2 2024 financial results conference call. The call is scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET. Financial results will be released via press release after market close on the same day. Investors can join the call using the toll-free number 1-888-596-4144 (Conference ID: 8584242) or via webcast. Management will discuss Q2 results and provide a general business update. A replay will be available until August 14, 2024. This event offers investors an opportunity to gain insights into ChromaDex's financial performance and future outlook.
ChromaDex Corp. (NASDAQ:CDXC) has launched the Niagen+ NAD+ Test Kit, exclusively available through its healthcare practitioner (HCP) channel. This innovative kit allows practitioners to measure patient blood NAD+ levels, enabling more personalized protocols using ChromaDex's NAD+-boosting products, Tru Niagen® and Niagen+.
The test kit features advanced dried blood spot (DBS) assay technology, ensuring NAD+ sample stability during transport. Analysis is conducted using high-resolution liquid chromatography/tandem mass spectrometry (LC-MS/MS) at a CLIA and CAP accredited laboratory. Results are available to both patients and doctors in about two weeks through the 1health platform.
This launch represents a significant advancement in NAD+ therapy, allowing practitioners to track NAD+ changes over time and create more effective patient protocols.
ChromaDex Corp. (NASDAQ:CDXC) has appointed Carlos Lopez as Senior Vice President, General Counsel, effective July 22, 2024. Lopez, a distinguished legal professional with expertise in the dietary supplements industry, will oversee the organization's legal function, including corporate governance, securities, intellectual property, and litigation. He will report directly to CEO Rob Fried.
Prior to joining ChromaDex, Lopez served as Vice President, General Counsel at The Vitamin Shoppe and has been on the board of The Natural Products Association. CEO Rob Fried expressed confidence in Lopez's expertise to help achieve ChromaDex's ambitious plans. Lopez stated his excitement to join ChromaDex, recognizing it as the gold-standard company pioneering NAD+ research and innovation.
ChromaDex Corp. (NASDAQ:CDXC) announces the debut of pharmaceutical-grade Niagen® (nicotinamide riboside chloride) for intravenous and injectable use at leading wellness clinics in August. Wells Pharma of Houston, a U.S. FDA-registered 503B outsourcing facility, will compound and distribute Niagen+ to select IV clinics.
Niagen IV offers superior tolerability, a 75% shorter infusion time, and a higher, faster rise in NAD+ blood levels compared to standard NAD+ IV treatments. With the global intravenous hydration therapy market valued at over $2.32 billion in 2022, ChromaDex is well-positioned to capture a significant share with its new product.
The company has secured orders beyond August and plans to expand into medical spas, with 11,000 locations in the US alone. Several prominent wellness clinics, including Clean Market/NutriDrip, Next Health, REVIV, and Restore Hyper Wellness, have expressed enthusiasm for the launch of Niagen+.
ChromaDex announced its inclusion in the Russell 2000® Index, effective July 1, 2024, as part of the annual Russell indexes reconstitution. This milestone, highlighted by CEO Rob Fried, marks ChromaDex's sustained growth and leadership in NAD+ research. ChromaDex's flagship product, Tru Niagen®, is renowned for its scientific rigor and quality standards, offering a clinically proven NAD+ supplement to combat age-related health decline. The Russell 2000 Index includes the 4,000 largest U.S. stocks, and ChromaDex's inclusion reflects its robust market capitalization and potential to drive long-term shareholder value.
ChromaDex Corp. (NASDAQ:CDXC) announced promising results from a Phase II clinical study on their patented nicotinamide riboside (NR) ingredient, Niagen®. Conducted with Northwestern University Feinberg School of Medicine, the study revealed significant improvements in functional mobility for individuals with peripheral artery disease (PAD). Participants showed increased six-minute walking distance and treadmill walking time, compared to a placebo. These findings, now published in Nature Communications, indicate the potential of NR to benefit PAD patients. However, further confirmation through larger clinical trials is necessary.
ChromaDex is set to launch Niagen+, the first pharmaceutical-grade intravenous and injectable Niagen (Nicotinamide Riboside Chloride or NRC).
FDA-approved for compounding by 503B outsourcing facilities, Niagen+ IV and injectable forms will be available at clinics nationwide starting August 2024. A clinical study showed no adverse side effects, superior tolerability, and a faster infusion time compared to NAD+ IV, with blood NAD+ levels peaking higher and sooner.
Niagen+ aims to transform the $2.32 billion global intravenous hydration therapy market. ChromaDex holds over 80 patents for its NAD+ precursors, ensuring robust IP protection.
ChromaDex (NASDAQ: CDXC) has received Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation from the FDA for its product candidate Nicotinamide Riboside Chloride (NRC), aimed at treating Ataxia Telangiectasia (AT), a rare and life-threatening condition affecting children. The company intends to submit an Investigational New Drug (IND) application to the FDA to commence human clinical trials. These trials will be led by Dr. Vilhelm Bohr, a scientific advisor to ChromaDex. The designations could accelerate NRC's development and provide benefits like market exclusivity and tax credits. CEO Rob Fried highlighted the potential of NRC to address unmet medical needs in rare diseases, which affect over 30 million people in the U.S.
ChromaDex (NASDAQ: CDXC) will participate in Renmark Financial Communications Inc.'s Virtual Non-Deal Roadshow on June 11, 2024, at 2:00pm PST. The event will feature presentations from CEO Rob Fried and CFO Brianna Gerber, who will discuss the latest investor presentation and participate in a live Q&A session. Stakeholders and investors are encouraged to register for the live event, though access may be A replay will be available on the ChromaDex Investor Relations website. For further details, visit www.chromadex.com.
FAQ
What is the current stock price of Chromadex (CDXC)?
What is the market cap of Chromadex (CDXC)?
What is Chromadex Corp's primary focus?
How does Chromadex generate its revenue?
What makes Chromadex's research unique?
What is the significance of nicotinamide riboside (NR) for Chromadex?
In which segments does Chromadex operate?
How does Chromadex ensure the quality and safety of its products?
How is Chromadex positioned within the competitive landscape?
What are the key benefits of Chromadex's integrated business model?
